Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Operating Leases (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Operating Leases data on record, last reported at $5.6 million in Q4 2025.

  • For Q4 2025, Operating Leases rose 117.02% year-over-year to $5.6 million; the TTM value through Dec 2025 reached $5.6 million, up 117.02%, while the annual FY2025 figure was $5.6 million, 117.02% up from the prior year.
  • Operating Leases reached $5.6 million in Q4 2025 per ARQT's latest filing, up from $5.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.6 million in Q4 2025 and bottomed at $2.1 million in Q2 2025.
  • Average Operating Leases over 5 years is $3.9 million, with a median of $3.9 million recorded in 2022.
  • Peak YoY movement for Operating Leases: tumbled 31.06% in 2024, then skyrocketed 117.02% in 2025.
  • A 5-year view of Operating Leases shows it stood at $4.8 million in 2021, then decreased by 13.76% to $4.1 million in 2022, then fell by 17.85% to $3.4 million in 2023, then dropped by 24.25% to $2.6 million in 2024, then soared by 117.02% to $5.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $5.6 million in Q4 2025, $5.3 million in Q3 2025, and $2.1 million in Q2 2025.